Your Product

Your Product

Back to main menu

Your Product

Services tailored to your product, ensuring the right development path, scalable processes, and consistent manufacturing outcomes.

Learn more
Your Stage

Your Stage

Back to main menu

Your Stage

At each stage, new challenges emerge. A single team and site ensure continuity and consistent execution across the product lifecycle.

Learn more
Our Services

Our Services

Back to main menu

Our Services

Integrated CDMO services designed for seamless progression from development through commercial manufacturing, under global regulatory standards.

Learn more
Resources

Resources

Back to main menu

Resources

Technical insights, practical guidance, and applied expertise to support decision‑making at every stage.

See all resources
About Us

About Us

Back to main menu

About Us

An overview of Groupe PARIMA, our mission, and our expertise in supporting the pharmaceutical industry.

Learn more
    En
    English
    Contact us

    Release Testing

    GMP release testing aligned with approved specifications for confident batch release.

    Drug Manufacturing banner

    Confident batch release testing

    Testing spans raw materials, packaging components, and finished products in support of batch release.

    Groupe PARIMA performs release testing starting with raw materials and packaging components. Incoming testing confirms identity and quality attributes to support material use and reliable downstream processing.

    Finished product release is supported by physicochemical and microbiological testing conducted in our internal GMP laboratories using validated or qualified methods aligned with approved specifications.

    Talk to our experts

    Release activities

    Release testing activities span materials, components, finished products, and stability to support batches across development and commercial stages.

    Card 01

    API and excipients testing

    Active pharmaceutical ingredients and excipients are tested to confirm identity and critical quality attributes prior to use in manufacturing.

    Card 02

    Packaging components

    Primary packaging components are evaluated to confirm identity and defined attributes relevant to product protection and compatibility.

    Card 03

    Finished drug products

    Finished products are tested using physicochemical and microbiologically validated methods aligned with release specifications.

    Card 04

    stability testing for shelf life

    Stability testing supports release and shelf‑life claims by monitoring product attributes and trends over defined storage conditions.

    Chemistry Testing Capabilities

    Our in-house equipment supports stage-appropriate method development and routine testing across chromatography, particle sizing, physical testing, and dissolution.

    01
    Card 01

    Potency determination

    Quantitative analysis to confirm active ingredient concentration and ensure therapeutic efficacy.

    02
    Card 02

    FTIR identification

    Fourier-transform infrared spectroscopy for rapid and reliable compound identification.

    03
    Card 03

    Impurity profiling 

    Detection and quantification of impurities and degradation products to support product safety and shelf-life evaluation.

    04
    Card 04

    Residual solvent analysis

    Ensures residual solvents are within safe, regulatory-approved limits, supporting compliance and patient safety.

    05
    Card 05

    Dissolution performance 

    Evaluates drug release profiles to predict bioavailability and support product performance claims.

    06
    Card 06

    Analytical testing

    Analytical testing includes viscosity, pH, moisture, particle and droplet size, density, and deliverable volume to support formulation performance.

    Release testing at Groupe PARIMA supports predictable batch disposition through controlled, specification‑driven testing.

    Microbiology Testing Capabilities

    Comprehensive microbiology testing to support product safety, quality control, and compliance with USP and EP requirements.

    01
    Card 01

    Aerobic Microbial Enumeration

    Measure aerobic bacteria using validated method in accordance with USP <61> and EP 2.6.12 to assess overall microbial load.

    02
    Card 02

    Fungal Microbial Enumeration

    Quantify yeast and mold levels using a validated analytical method in accordance with USP <61> and EP 2.6.12 to ensure product safety.

    03
    Card 03

    Microbial Suitability Testing

    Screen for objectionable microorganisms as defined in USP <62>, USP <60>, and EP 2.6.13, based on dosage form and intended use.

    04
    Card 04

    Microbial Identification Testing

    Identify microbial isolates to support contamination investigations and corrective actions.

    05
    Card 05

    Preservative Efficacy Testing

    Confirm preservative system efficacy in multi-dose products in accordance with USP <51>.

    Resources

    Access technical insights and guidance to support informed decisions around release testing and analytical strategy.

    Groupe PARIMA
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Read more
    Groupe PARIMA
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Read more
    Groupe PARIMA
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Read more
    Groupe PARIMA
    How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
    Read more
    Groupe PARIMA
    How Early API Characterization Can Reduce Formulation and Scale-up Risks
    Read more
    Groupe PARIMA
    Topical 101: A Guide to Complex Dermatology Formulation Development
    Read more

    See all Resources

    Contact us

    Discuss your project needs.

    Connect with our team to review your release testing needs across materials, packaging components, and finished products.